This was experimentally validated using BET inhibitors, which pharmacologically disrupted these long enhancer-enriched regions and resulted in the reduction of IFNα-induced TRAIL expression, specifically in the cancer cell lines in which TRAIL is associated with enhancer clusters. The gene discussed is IFNA2; the disease is cancer.